Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer

Author(s): Vinay K. Venishetty, Werner J. Geldenhuys, Tori B. Terell-Hall, Jessica I.G. Griffith, Gregory R. Sondag, Fayez F. Safadi, Paul R. Lockman*

Journal Name: Current Cancer Drug Targets

Volume 17 , Issue 5 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Background: Brain cancer from metastasized breast cancer has a high mortality rate in women. The treatment of lesions is hampered in large part by the blood-brain barrier (BBB), which prevents adequate distribution of anti-cancer compounds to brain metastases.

Method: In this study we used a novel screening method to identify candidate molecules that are well-suited to utilizing the BBB choline transporter for distribution into the brain parenchyma.

Results: From our screen we identified two compounds, Ch-1 and Ch-2 that were able to reduce the brain tumor burden in a murine mouse model of brain metastasis of breast cancer. These compounds also significantly increased the survival of mice by more than 10 days. Mechanistic studies indicated that Ch-1 is able to prevent the activation of the pro-survival mitogen-activated kinases (MAPKs) by osteoactivin (OA; Glycoprotein nonmetastatic melanoma protein B GPNMB).

Conclusion: The results from this study show that nutrient transporter virtual screening is a viable novel alternative to traditional drug screening programs to identify anti-cancer compounds for the treatment of brain cancers.

Keywords: Drug resistance, CNS, distribution, brain cancer, drug discovery, chemotherapy, ADME.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [479 - 485]
Pages: 7
DOI: 10.2174/1568009617666161121123948
Price: $65

Article Metrics

PDF: 38